Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: England NLM ID: 101125414 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7682 (Electronic) Linking ISSN: 14712598 NLM ISO Abbreviation: Expert Opin Biol Ther Subsets: MEDLINE
    • Publication Information:
      Publication: 2015- : Abingdon, Oxford : Taylor & Francis
      Original Publication: London : Ashley Publications Ltd., c2001-
    • Subject Terms:
      Biliary Tract Neoplasms*/immunology ; Biliary Tract Neoplasms*/drug therapy ; Biliary Tract Neoplasms*/therapy ; Immune Checkpoint Inhibitors*/therapeutic use ; Immunotherapy*; Humans ; Biomarkers, Tumor/immunology ; Animals
    • Abstract:
      Introduction: Recently, immunotherapy has offered new hope for treating biliary tract cancer (BTC). However, several issues are to be considered, including the lack of validated predictive biomarkers that could help to identify patient groups which are most likely to benefit from such therapeutic approaches.
      Areas Covered: In the current article, we will provide an overview of recent results and ongoing and future research directions of immunotherapy in BTC, with a special focus on recently published, practice-changing data, and ongoing active and recruiting clinical trials.
      Expert Opinion: At this moment, dozens of clinical trials in phases I to III are evaluating the role of cancer immunotherapy in this setting, with the hope of adding more therapeutic options for BTC patients. Future research must focus on the development of novel agents and combinations, but the validation of biomarkers remains an urgent need. As more research results emerge, novel combinatorial strategies are destined to further transform the treatment paradigm for this heterogeneous and aggressive tumor type.
    • Contributed Indexing:
      Keywords: Biliary tract cancer; cholangiocarcinoma; durvalumab; immune checkpoint inhibitors; immunotherapy; pembrolizumab
    • Accession Number:
      0 (Immune Checkpoint Inhibitors)
      0 (Biomarkers, Tumor)
    • Publication Date:
      Date Created: 20241115 Date Completed: 20241204 Latest Revision: 20241204
    • Publication Date:
      20241204
    • Accession Number:
      10.1080/14712598.2024.2431088
    • Accession Number:
      39545466